NOVUMGEN LIMITED

Novumgen Limited is a forward‑looking life‑science company dedicated to bringing the future of healthcare to patients and prescribers today. Drawing on 18 years of excellence, the firm accelerates drug development from concept to market, leveraging a deep understanding of both regulated and semi‑regulated environments to move assets swiftly through the pipeline.

The company’s portfolio spans more than 300 innovative products, with a particular focus on oncology, inflammation and immunology, rare diseases and pharmacogenomics. Novumgen offers a suite of services that include product licensing, strategic collaborations, technology transfer and contract‑manufacturing (CMO), supported by a robust pipeline of ready dossiers (e‑CTD, CTD, ACTD) and validated finished‑formulation capabilities. By partnering with academic, commercial and biotech organisations, Novumgen aims to expand its pipeline of niche therapies and deliver real‑world benefits to patients worldwide.

Guided by a diverse advisory board and a leadership team that blends scientific expertise with commercial acumen, Novumgen invites innovators with promising drug ideas to join its collaborative network, helping to shape the next generation of medicines.